Q5102 — Injection, infliximab, biosimilar, 10 mg
Q5102 is a HCPCS Level II code for injection, infliximab, biosimilar, 10 mg. It belongs to the Temporary Codes section. It was terminated on March 31, 2018 and is not valid on new claims.
This code has been terminated
CMS terminated Q5102 on March 31, 2018. It stays in the file as history — a claim you are auditing from before that date may legitimately carry it — but it must not appear on a new claim. The adjacent codes below are the usual place to look for its replacement.
Medicare coverage: Special coverage instructions apply
There are published conditions attached to this code. Check the applicable coverage policy before billing it: the code being valid is not the same as the service being covered.
From the coverage field of the CMS Alpha-Numeric HCPCS File, release 2026Q3-Jul. This states Medicare’s position on the code, not on your particular claim.
The CMS record for Q5102
- Long descriptor
- Injection, infliximab, biosimilar, 10 mg
- Short descriptor
- Inj., infliximab biosimilar
- Added
- July 1, 2016
- Terminated
- March 31, 2018
- BETOS
- O1E
- Pricing indicator
- 51 — Other
The official wording. This is what the code means.
CMS's 28-character form, which is what shows up on a remittance advice.
When CMS introduced the code.
When CMS retired it.
Berenson-Eggers Type of Service — CMS's own analytic grouping.
Drugs.
Codes adjacent to Q5102
HCPCS has no hierarchy — related items simply sit next to each other in the numbering. If Q5102 is not quite right, the correct code is very often within a few positions of it.
- Q5007Hospice care provided in long term care facility
- Q5008Hospice care provided in inpatient psychiatric facility
- Q5009Hospice or home health care provided in place not otherwise specified (nos)
- Q5010Hospice home care provided in a hospice facility
- Q5098Injection, ustekinumab-srlf (imuldosa), biosimilar, 1 mg
- Q5099Injection, ustekinumab-stba (steqeyma), biosimilar, 1 mg
- Q5100Injection, ustekinumab-kfce (yesintek), biosimilar, 1 mg
- Q5101Injection, filgrastim-sndz, biosimilar, (zarxio), 1 microgram
- Q5103Injection, infliximab-dyyb, biosimilar, (inflectra), 10 mg
- Q5104Injection, infliximab-abda, biosimilar, (renflexis), 10 mg
- Q5105Injection, epoetin alfa-epbx, biosimilar, (retacrit) (for esrd on dialysis), 100 units
- Q5106Injection, epoetin alfa-epbx, biosimilar, (retacrit) (for non-esrd use), 1000 units
- Q5107Injection, bevacizumab-awwb, biosimilar, (mvasi), 10 mg
- Q5108Injection, pegfilgrastim-jmdb (fulphila), biosimilar, 0.5 mg
- Q5109Injection, infliximab-qbtx, biosimilar, (ixifi), 10 mgterminated
- Q5110Injection, filgrastim-aafi, biosimilar, (nivestym), 1 microgram
Questions about Q5102
What is HCPCS code Q5102?
Q5102 is a HCPCS Level II code for injection, infliximab, biosimilar, 10 mg. It sits in the Temporary Codes section.
Does Medicare cover Q5102?
The CMS HCPCS file marks Q5102 as "Special coverage instructions apply". There are published conditions attached to this code. Check the applicable coverage policy before billing it: the code being valid is not the same as the service being covered.
Is Q5102 still valid?
No. Q5102 was terminated on March 31, 2018 and should not be used on new claims.